Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.

Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.

http://www.wikidata.org/entity/Q33441606

about

Superior efficacy of the antifungal agent ciclopirox olamine over gemcitabine in pancreatic cancer models.

P2860

Q52657095-83F9FE72-CAE7-4520-B3EA-756462C023BB

P2860

Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.

http://www.wikidata.org/entity/Q33441606

description

2017 nî lūn-bûn

@nan

2017 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Efficacy and safety of gemcita ...... is of individual patient data.

@ast

Efficacy and safety of gemcita ...... is of individual patient data.

@en

type

label

Efficacy and safety of gemcita ...... is of individual patient data.

@ast

Efficacy and safety of gemcita ...... is of individual patient data.

@en

prefLabel

Efficacy and safety of gemcita ...... is of individual patient data.

@ast

Efficacy and safety of gemcita ...... is of individual patient data.

@en

P1433

Q33441606-67D157B0-4D1C-455A-9C41-9598567921A9

P1476

Q33441606-7B3F69A4-4116-4210-BB22-338A3361CCC2

P2093

Q33441606-43AF91C1-FF38-4E60-9487-064E507DAF2E

Q33441606-4899A3B9-2D41-40D9-9F4C-E03CAE7A2F0A

Q33441606-5159DCD3-C741-4B40-9BE8-58BFBFF64091

Q33441606-63E0FF92-D3BD-49C7-9F41-6976C126CE5E

Q33441606-719527D5-BC58-47A7-ACDE-1160271EB71F

Q33441606-81204DB7-252D-4579-B58C-682DBCBD4CA1

Q33441606-99F54D4E-6166-48BE-9370-D5F83A7D2982

Q33441606-BE8774B4-34C4-4EC8-8278-AD8D0609BC39

Q33441606-F8EDF487-3E7A-4166-BA55-5F26DCD6640B

P2860

Q33441606-1972D767-2903-4961-9ADA-90C0C5E6F4FA

Q33441606-1A763A00-1ABD-46EC-9E1B-EE34ABE4C389

Q33441606-2D34109D-FF75-45F1-8957-C8748B24531B

Q33441606-3E95861D-0EFD-41A7-B81A-AD7465696736

Q33441606-3EFF77D2-B76C-4100-BCBF-98B7E22A3AB2

Q33441606-40D562F7-36A3-488C-AA31-25AEBBC896D8

Q33441606-52689D40-76BD-43C5-ACA3-C79B7098CE2E

Q33441606-52F3774E-0FD8-4FCE-A43F-27B07E680DC5

Q33441606-5C9EEC9C-595E-4A1F-AE6D-917AE3DE9F45

Q33441606-6048D568-EA84-4CA7-8BB8-9171C41A3BA5

P2888

Q33441606-91ECF470-3EFC-40EC-B622-D4274AC1B7C5

P304

Q33441606-6E7B5C91-DA83-4125-9E1C-16D57AD63A40

P31

Q33441606-1D3C9C9C-9DAB-458F-B3C1-7ECBE45773AA

P356

Q33441606-F7157F40-71DF-48B8-A62F-2885924FC53B

P407

Q33441606-EE63D5D5-B873-4293-BBB3-57D2A85796DB

P433

Q33441606-DEA899FA-6244-4365-AF6F-6553C4A4D70B

P478

Q33441606-5663EA42-A5B7-477D-8730-06838BC9981C

P577

Q33441606-F844FB17-BB12-466F-908D-7247D332D6E6

P6179

Q33441606-0867AF2E-5D64-4D04-8E1E-DF012A3AAE56

P698

Q33441606-235FEAAC-DF56-4E6F-A3BD-CB1CD30ED73E

P932

Q33441606-7F400AC2-20F5-4128-8E8D-D26C918D201A

P356

P1433

British Journal of Cancer

P1476

Efficacy and safety of gemcita ...... is of individual patient data.

@en

P2093

Chikuma Hamada

http://www.w3.org/2001/XMLSchema#string

Hiroshi Ishii

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Isayama

http://www.w3.org/2001/XMLSchema#string

Junji Furuse

http://www.w3.org/2001/XMLSchema#string

Shogo Imai

http://www.w3.org/2001/XMLSchema#string

Shota Okamura

http://www.w3.org/2001/XMLSchema#string

Takaaki Ikari

http://www.w3.org/2001/XMLSchema#string

Takuji Okusaka

http://www.w3.org/2001/XMLSchema#string

Yousuke Nakai

http://www.w3.org/2001/XMLSchema#string

P2860

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

P2888

P304

1544-1550

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2017.128

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085142446

http://www.w3.org/2001/XMLSchema#string

P698

28472821

http://www.w3.org/2001/XMLSchema#string

P932

5518857

http://www.w3.org/2001/XMLSchema#string